chloroquine and derivatives - versus control - for COVID-19 severe or critically pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.80 [0.52, 1.24]< 10%1 study (1/-)84.0 %some concernnot evaluable moderatecrucial-
deaths 0.80 [0.52, 1.24]< 10%1 study (1/-)84.0 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.80 [0.52, 1.24]< 10%1 study (1/-)84.0 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 1.05 [0.74, 1.48]> 10%1 study (1/-)61.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.01 [0.72, 1.42]> 10%1 study (1/-)52.3 %some concernnot evaluable moderateimportant-
off oxygenation 0.98 [0.64, 1.51]> 10%1 study (1/-)46.4 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.